GlassScriptPhysician profile
Megan Sterling
NPI 1114666229
$2,458.46
in general payments reported to CMS, 2019-2025
26 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,257 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.83 | 2024-2025 | |
| Ucb, INC. | $187.34 | 2024-2025 | Nayzilam, Briviact |
| Argenx US, INC. | $159.13 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $113.20 | 2024-2025 | Tysabri, Vumerity |
| Harmony Biosciences LLC | $110.84 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $107.78 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $105.88 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Emd Serono, INC. | $100.39 | 2024-2025 | |
| Neurelis, INC. | $100.38 | 2024-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $92.01 | 2024-2025 | Ongentys, Rytary |
| Eisai INC. | $87.57 | 2024-2025 | |
| Axsome Therapeutics, INC. | $81.20 | 2024-2025 | Sunosi, Symbravo |
| Neurocrine Biosciences, INC. | $73.34 | 2024-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $65.89 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $59.61 | 2025 | Austedo Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $55.15 | 2024-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $54.53 | 2024-2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $45.15 | 2024 | |
| Merz Pharmaceuticals, LLC | $44.82 | 2025 | Inbrija, Xeomin |
| Celgene Corporation | $43.79 | 2024-2025 | Zeposia |
| Boston Scientific Corporation | $27.28 | 2024 | Wavewriter Alpha Prime 16 |
| Sk Life Science, INC. | $24.29 | 2025 | |
| Pfizer INC. | $23.23 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.51 | 2024 | Hyqvia |
| Livanova USA, INC. | $20.88 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ge Healthcare | $14.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.